Roche AG and Eli Lilly and Co., two drugmakers racing to develop treatments for some of the least understood brain disorders, may gain the most from a U.S. government boost in funding to fully map the human brain.
The new partnership between Community Health Network and Wishard Health Services could put a third health care entity in an awkward position: the Indiana University School of Medicine. Virtually all of the nearly 1,100 physicians who practice at Wishard Memorial Hospital and its community clinics come from the IU medical school.
Half of the candidates to replace retiring dean Dr. Craig Brater are from the IU medical school and the other half are outsiders, according to a release issued Monday by the Indiana University School of Medicine.
Community Health Network’s new partnership with Wishard Health Services will create a primary-care behemoth that the systems argue will put them in the best position possible to handle the changes coming from federal health reform.
The partnership will create a new board to oversee and coordinate the operations of both systems, according to internal messages sent to Community stakeholders. Community Health CEO Bryan Mills will be the CEO of the new joint-operating entity.
Former Amerigroup Corp. CEO James Carlson will leave WellPoint Inc., the company said Friday—three days after he was passed over for the Indianapolis-based insurer’s top job.
A federal audit released Friday recommends Indiana's human services agency refund more than $5.8 million in Medicaid funds because Logansport State Hospital did not show it had complied with special conditions for psychiatric hospitals.
Anthem Blue Cross and Blue Shield has selected Community Health Network to be the “exclusive provider” for a new kind of health insurance plan—a sharp departure from Anthem’s typical strategy of offering the broadest network of hospitals and doctors.
Diagnostic products maker Qiagen NV said Wednesday that it will work with Eli Lilly and Co. to develop new tests that could identify patients who could be helped by Lilly’s drugs.
Indiana Gov. Mike Pence is asking the federal government to approve a three-year extension of the Healthy Indiana Plan health savings accounts in lieu of an expansion of a federal Medicaid system he calls "broken."
The Indianapolis-based health insurer saw its stock tumble as much as 4.8 percent Wednesday morning after it unexpectedly named career hospital executive Joe Swedish to be its next CEO.
The Indiana Senate Public Health Committee is advancing a proposal to expand Medicaid using the state's health savings account plan.
Joe Swedish, CEO of Michigan-based Trinity Health since December 2004, will replace Angela Braly, who was forced out in August.
Don Kelso is executive director of the Indiana Rural Health Association. The trade group is trying to help its members navigate the changes coming from health care reform and the financial pressures being created by federal budget cuts. The association recently launched a service for its members called SuiteStats, which is data-management software to help hospital executives identify areas ripe for cost-cutting.
Up until now, Gov. Mike Pence and his fellow Republicans in the Legislature have been playing a game of poker with the Obama administration over a potential expansion of Indiana’s Medicaid program. But all of a sudden, Indiana’s hand just got quite a bit weaker.
To understand why Indiana’s life sciences entrepreneurs are frustrated with the flow of venture capital, look no further than this statistic from a recent PricewaterhouseCoopers report: 2012 was the slowest year for first-time life sciences investment since 1995.
Democratic leaders in the Indiana General Assembly are seeking expanded Medicaid coverage with the argument that it will lower health care costs statewide.
Across the four largest hospital systems in central Indiana, six physicians received more than $1 million in compensation in 2011 while two others received more than $900,000 and nine others received $700,000 or more, according to the hospitals’ most recent reports to the IRS.
Eli Lilly said it is halting testing of experimental drug tabalumab because the studies show the medicine is not effective. The company said it expects to take a $50 million charge in the first quarter related to the research expenses from the drug.
Elona Biotechnologies Inc., which has been struggling to repay Greenwood for more than $8 million in economic development incentives, says it has solution to its financial problems.
